DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Artis Capital Management, L.P.
Artis Capital Management, L.P.
Private equity with venture activity · probableSan Francisco, CAartiscapital.comSEC registered investment adviser
At ARTIS, we partner with bold founders to transform the human condition with frontier technologies.
registered adviser; venture funds are 35% of 10 private funds
Importance
28
moderate
Active deployment
30
moderate
Emerging
0
low
Completeness
69
high
Freshness
100
high
Research priority
12
low
Identity and regulatory footprint
- Headquarters
- San Francisco, CAadviserinfo.sec.gov
- Office address
- 988 MARKET ST., San Francisco, CA, 94102adviserinfo.sec.gov
- Business phone
- 415-344-6200adviserinfo.sec.gov
- Website
- HTTPS://WWW.ARTISCAPITAL.COM
- SEC adviser type
- registered investment adviseradviserinfo.sec.gov
- SEC exemption claimed
- unknown
- Latest Form ADV
- Mar 30, 2016
- Private funds reported
- 10 (0 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $17.8Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Regulatory AUM
- $13.2Mthe adviser's RAUM, a regulatory measure, never a fund size
- Employees
- 6
- Owners on Schedule A
- Artis Capital Management, Inc. (General Partner), NA
- business phone
- 415-344-6200adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
57 observed deals
Stated (the firm’s website)
- Sectors
- ai, healthcare, biotech, medtech, consumer, deep tech
- Stages
- not stated or not yet read
- Geography
- usa
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 89%Other Technology 5%Other 4%Biotechnology 2%
lead rate n/afollow-on rate n/anew logos, 12 months 57
Funds and vehicles
1 reported, 2 no longer reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Artis Ventures Fund, LLC | Fund | 2011 form d first sale | Harvest | $8.5M Mar 30, 2016 | 1 | $5.0M | Jan 12, 2012 |
| Artis Nimble Storage Spv, L.P. | SPV or co-invest vehicle | 2013 adv first reported | Wound down | $36.2M Jul 30, 2014 | 18 | unknown | unknown |
| Apg2, L.P. | Fund | unknown | Wound down | $7.7M May 4, 2020 | 12 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
30 current, 1 departed
Sneha Jain
AnalystChief Fellow, Cardiovascular Medicine, Stanford
Craig Herkert
Board or advisoryExecutive Chairperson of the Board, Quirch Foods
Al Mezzaroba
Founder or executiveFrmr President and CEO, Lower Bucks Hospital
ANN Lee-Karlon
Founder or executiveCEO EpiBiologics; Frmr SVP, Research & Early Development, Genentech
Bahija Jallal
Founder or executiveCEO, Immunocore; Frmr President, MedImmune and EVP, AstraZeneca
Kash Chandarana
Founder or executiveCo-Founder Luxe Brand Assets; Alma Hotel Management
Roohi Jeelani
Founder or executiveCEO and Founder ONTO Health
Sara Kenkare-Mitra
Founder or executivePresident, Head of R&D, Alector; Frmr SVP Development Sciences, Genentech
William Carson
Founder or executiveFrmr CEO & Chairman of the Board, Otsuka Pharmaceutical
Paul Johnson
General partnerGeneral Partner, Flex Capital
Stuart Peterson
Managing partnerManaging Partner
Michael Yang
Operating partnerOperating Partner
Leena Das-Young
OtherFrmr Executive, Guardant Health, Pfizer, Bayer
Megan Daugherty
OtherChief of Staff
Prashant Mali
OtherAs a Pioneer, Prashant brings technical expertise and entrepreneurship experience to the ARTIS team and portfolio.
Wendy Mayer
OtherFrmr Head Of Strategy, Pfizer
Austin Walne
PartnerSenior Partner
Henry Klingenstein
PartnerPartner
Jeff Sheedy
PartnerPartner
Omair Khan
PartnerPartner
Richard Daniels
PartnerFrmr CIO, Kaiser Permanente
Ruchita Sinha
PartnerSenior Partner
Stuart Leonardo Peterson
PartnerSole Shareholder · since Jan 1, 2004
Featured Pioneers
Platform and operationsInvestment & Operations
Robert Allan Riemer
Platform and operationsChief Financial Officer / Chief Compliance Officer · since Jan 1, 2012
Robert Riemer
Platform and operationsChief Operating Officer
Simon Helfgott
PrincipalDirector Of Education, BWH, Harvard Medical School
Niraj Mehta
Venture partnerVenture Partner
Quita Highsmith
Vice presidentVP Population Health, Pharma
Richard Fuchs
Vice presidentVP of Strategy and Innovation at Walmart Health Head of Growth at Elevance Health CEO OPYN Health
1 departed (kept with end dates)
- Robert Todd Moodey · Chief Operating Officer · Aug 1, 2007 to Mar 31, 2014 Inference
Investments on record
57 edges, 57 companies, 0 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
40 relationships from shared deals, counted for the whole firm
Artis Ventures Management, L.P. 57 shared · very strongCatalio Capital Management, LP 2 shared · recurringAsset Management Ventures, LLC 2 shared · recurringGlynn Capital Management, LLC 2 shared · recurringAnthemis 1 shared · one timeKhosla Ventures, LLC 1 shared · one timeLifeforce Capital Management, LLC 1 shared · one timeInnovating Capital Management, LLC 1 shared · one timeMadrona Venture Group, LLC 1 shared · one timeSempervirens Ventures LLC 1 shared · one timeBeliade 1 shared · one timeBling Capital LLC 1 shared · one timeMotivate Capital Management, LLC 1 shared · one timemark vc 1 shared · one timeScout Vc, LLC 1 shared · one timeU.S. Venture Partners 1 shared · one timeBreakout Management, LLC 1 shared · one timeLevel One Fund 1 shared · one timeCommonweal Ventures Management, LLC 1 shared · one timeSanderling Management Company, LLC 1 shared · one time137 Ventures Management, LLC 1 shared · one timeSapphire Ventures, LLC 1 shared · one timeParadigm Operations LP 1 shared · one timeE2jdj 1 shared · one timePvglobal 1 shared · one timeThe Venture Collective LLC 1 shared · one timeUpper90 1 shared · one timeThe Legaltech Fund Management Co., L.L.C. 1 shared · one timeAcequia Capital Management LLC 1 shared · one timeHaymaker Ventures LLC 1 shared · one timeInterplay Ventures Early Stage Management LLC 1 shared · one timeAdit Ventures Management, LLC 1 shared · one timeCRV, LLC 1 shared · one timeArch Venture Partners 1 shared · one timeDlab Ventures LLC 1 shared · one timeStory Ventures 1 shared · one timeDoorga Capital 1 shared · one timeSwift Ventures 1 shared · one timeTrinity Ventures 1 shared · one timeLerer Hippeau Ventures Management, LLC 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
3 dated events
- Mar 30, 2016Artis Ventures Fund, LLC no longer reported on Form ADV by Artis Capital Management, L.P.Fund no longer reportedFundsInferenceArtis Ventures Fund, LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 31, 2014Robert Todd Moodey (Chief Operating Officer) no longer on Schedule A of Artis Capital Management, L.P.
- Feb 6, 2012Artis Capital Management, L.P. first filed Form ADV (IA)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Private equity with venture activity (probable, 75%, cls-1)registered adviser; venture funds are 35% of 10 private funds
Evidence
41 observations from 2 sources